

Intercell AG
Document according to section 75a of the Austrian Stock Exchange Act (SEA)
of mandatory announcements during the fiscal year 2010

Date	Type	Description	Source
January 4, 2010	Corporate News announcement	Intercell starts an additional efficacy trial for its patch-based investigational Travelers' Diarrhea Vaccine System in Asia	Euro ad hoc system/ www.intercell.com
February 11, 2010	Ad-hoc announcement	Intercell obtains results from its first Phase I investigational vaccine study for Streptococcus pneumoniae	Euro ad hoc system/ www.intercell.com
March 2, 2010	Ad-hoc announcement	Intercell announces Q4 and preliminary full year 2009 financial results	Euro ad hoc system/ www.intercell.com/ www.issuerinfo.oekb.at
March 4, 2010	Corporate News announcement	Joint Committee on Vaccination and Immunisation (JCVI) in the UK broadens Japanese Encephalitis immunization recommendation to include Intercell vaccine	Euro ad hoc system/ www.intercell.com
April 23, 2010	Publication of Annual Accounts	Annual Financial Report	Euro ad hoc system/ www.intercell.com/ www.issuerinfo.oekb.at
May 6, 2010	Ad-hoc announcement	Intercell acquires antibody technology platform to further exploit its capabilities to combat infectious diseases	Euro ad hoc system/ www.intercell.com
May 10, 2010	Corporate News announcement	Intercell and Boehringer Ingelheim Vetmedica GmbH enter into strategic partnership to develop animal vaccines	Euro ad hoc system/ www.intercell.com
May 11, 2010	Ad-hoc announcement	Intercell announces Q1 2010 results and updates on R&D progress	Euro ad hoc system/ www.intercell.com/ www.issuerinfo.oekb.at
May 25, 2010	Corporate News announcement	Intercell Recognized by U.S. Department of Defense for Development of Japanese Encephalitis Vaccine, IXIARO®	Euro ad hoc system/ www.intercell.com

Date	Type	Description	Source
May 26, 2010	Annual General Meeting	Invitation to the General Meeting	Euro ad hoc system/ www.intercell.com/ Wiener Zeitung
June 4, 2010	Corporate News announcement	Announcement regarding the upcoming Annual Shareholders' Meeting	Euro ad hoc system/ www.intercell.com
June 8, 2010	Corporate News announcement	Intercell completed the acquisition of Cytos' antibody technology platform	Euro ad hoc system/ www.intercell.com
June 25, 2010	Annual General Meeting	Resolutions of the General Meeting	Euro ad hoc system/ www.intercell.com
July 2, 2010	Ad-hoc announcement	Intercell AG announced the results of a Phase II clinical trial of its investigational Vaccine Enhancement Patch (VEP) system for avian H5N1 influenza – Intercell intends to conduct further clinical studies	Euro ad hoc system/ www.intercell.com
July 13, 2010	Corporate News announcement	Swiss authorities (Swissmedic) grant product approval for Intercell's IXIARO®	Euro ad hoc system/ www.intercell.com
July 20, 2010	Ad-hoc announcement	Intercell AG / Publication pursuant to Sections 4 and 5 of the Publication Ordinance 2002 INTERCELL AG, ISIN: AT0000612601	Euro ad hoc system/ www.intercell.com
July 30, 2010	Number of voting rights	Announcement of new total number of voting rights according to section 93 subs. 2 SEA	Euro ad hoc system/ www.intercell.com
August, 17 2010	Ad-hoc announcement	Announcement of Q2 and Half Year financial report and business update	Euro ad hoc system/ www.intercell.com/ www.issuerinfo.oekb.at
August, 2 2010	Total number of voting rights	Announcement of new total number of voting rights according to section 93 subs. 2 SEA	Euro ad hoc system/ www.intercell.com
August, 30 2010	Corporate News announcement	Publication pursuant to Section 7 of the Publication Ordinance 2002	www.intercell.com

Date	Type	Description	Source
September, 30 2010	Ad-hoc announcement	Intercell AG appoints Staph Leavenworth Bakali as Chief Business Officer - Management Board addition with a successful proven track record in vaccines industry	Euro ad hoc system/ www.intercell.com
October, 21 2010	Ad-hoc announcement	Intercell and Romark join forces in combining therapies against Hepatitis C	Euro ad hoc system/ www.intercell.com
October, 25 2010	Ad-hoc announcement	Intercell reports positive results from its Phase II Pseudomonas aeruginosa investigational vaccine study for certain hospital-acquired infections	Euro ad hoc system/ www.intercell.com
November, 9 2010	Ad-hoc announcement	Intercell AG announces Q3 2010 results and updates on R&D progress and management	Euro ad hoc system/ www.intercell.com/ www.issuerinfo.oekb.at
November, 18 2010	Corporate News announcement	Intercell announces initial results of Phase II clinical trial evaluating V710, an investigational Staphylococcus aureus vaccine, in patients with end-stage renal disease	Euro ad hoc system/ www.intercell.com
December, 12 2010	Ad-hoc announcement	Intercell provides update on clinical trials for the patch-based Travelers' Diarrhea vaccine	Euro ad hoc system/ www.intercell.com
December, 15 2010	Corporate News announcement	Publication pursuant to Sections 4 and 5 of the Publication Ordinance 2002	Euro ad hoc system/ www.intercell.com
December, 15 2010	Corporate News announcement	Report pursuant to Section 159 Para 3 and Para 2 lit 3 and Section 95 Para 6 of the Austrian Stock Corporation Act	Euro ad hoc system/ www.intercell.com
December, 22 2010	Corporate News announcement	Intercell starts a Phase I clinical trial for a new vaccine to prevent Clostridium difficile infections	Euro ad hoc system/ www.intercell.com